Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard Finn; Peter Galle; Josep Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo Abada; Masatoshi Kudo; REACH-2 study investigators

doi:10.1016/S1470-2045(18)30937-9

Retour

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Article de revue

Avec comité de lecture

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard Finn, Peter Galle, Josep Llovet, Eric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, …

The lancet oncology, Vol.20(2), pp.282-296

02/2019

DOI: https://doi.org/10.1016/S1470-2045(18)30937-9

PMID: 30665869

Résumé

Alpha-Fetoproteins / analysis

Antibodies, Monoclonal, Humanized /administration & dosage

Antineoplastic Agents / administration & dosage

Cancer

Carcinoma, Hepatocellular / blood

Carcinoma, Hepatocellular / drug therapy

Life Sciences

Liver Neoplasms / blood

Liver Neoplasms / drug therapy

Sorafenib / administration & dosage

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Créateurs - sans rôle: Andrew Zhu - Harvard Medical School [Boston]
Yoon-Koo Kang - Asan Medical Center
Chia-Jui Yen - National Cheng Kung University
Richard Finn - David Geffen School of Medicine [Los Angeles]
Peter Galle - University Medical Center [Mainz]
Josep Llovet - Icahn School of Medicine at Mount Sinai
Eric Assenat - Centre Hospitalier Régional Universitaire [Montpellier]
Giovanni Brandi - University of Bologna
Marc Pracht - CRLCC Eugène Marquis
Ho Yeong Lim - Sungkyunkwan University [Suwon]
Kun-Ming Rau - Chang Gung Memorial Hospital [Taipei]
Kenta Motomura - Fukuoka University
Izumi Ohno - University of Tokyo [Kashiwa Campus]
Philippe Merle - Hôpital de la Croix-Rousse
Bruno Daniele - G Rummo Hospital
Dong Bok Shin - Gachon University Gil Medical Center [Incheon, Republic of Korea]
Guido Gerken - Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
Christophe Borg - Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique
Jean-Baptiste Hiriart - Hôpital Haut-Lévêque [CHU Bordeaux]
Takuji Okusaka - Tokyo Medical University
Manabu Morimoto - Yokohama University School of Medecine
Yanzhi Hsu - Eli Lilly and Company [Indianapolis]
Paolo Abada - Eli Lilly and Company [Indianapolis]
Masatoshi Kudo - Kindai University
REACH-2 study investigators
Détails de publication: The lancet oncology, Vol.20(2), pp.282-296
Éditeur: Elsevier
Nombre de pages: 15
Identifiants: 99139644009311
Unité académique: Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Journal article